DUAL V and DUAL VII: Treatment Intensification with IDegLira

Duration

< 15 mins

Profession

Allied Health

Physician

Nursing

Specialist

Pharmacy

Student

Medical Resident

# of Credits

0.0

Accreditation

N/A

Expiry Date

2020-05-23

Once-daily combinations of a basal insulin with a GLP-1 RA offer two agents with complementary mechanisms of action for better glycemic control in type 2 diabetes mellitus, while reducing risks of hypoglycemia and weight gain, and allowing for simplification of the treatment regimen. The DUAL V and DUAL VII studies have demonstrated the benefits of IDegLira, a once-daily combination of insulin degludec and liraglutide in patients uncontrolled on basal insulin.

Unaccredited

Sonja Reichert, MD, MSc, CCFP

Stewart Harris, MD, MPH, FCFP, FACPM



Related Courses